Can a pill quiet the adrenal Glands' hormone overdrive?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Male or female * Age \> 18 years at time of signing informed consent. * Diagnosed with Primary Aldosteronism (PA) according to Endocrine Society guidelines * Presence of one or more adrenal nodules, (diameter 0.5-2.5 cm) on CT, PET-CT, or MRI, with characteristics (e.g. washout) of adenomas * Suppressed cortisol after overnight dexamethasone * Willing to take baxdrostat for 6 months and attend follow-up visits * Willing to undergo PET-CT imaging * Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening. * Serum potassium (K+) level ≥ 3.5 and \< 5.0 mmol/L * Negative pregnancy test for female participants of childbearing potential * Able and willing to provide written consent Exclusion criteria * \<18 years of age * Current or prior treatment (within 1 month before screening) with angiotensin-receptor blockers in combination with ACEIs. * Serum sodium level \< 135 mmol/L at screening, determined as per central laboratory. * The following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation. * New York Heart Association functional Heart Failure class IV at Screening. * Known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease. * Known severe hepatic impairment. * Uncontrolled diabetes with HbA1c \> 10.0% (86 mmol/mol) at screening. * Participants suspected to have severe cardiac hypertrophy. * Treatment with any MRAs or potassium-sparing diuretics within 1 month prior to screening. * Treatment with potassium binders within 1 month prior to screening. * Is expected to receive or is receiving any of the exclusionary drugs such as strong inducers of cytochrome P450 (CYP) 3A, chronic (taken more than 3 times a week for more than 3 months) use of NSAIDs, MRAs or chronic use of systemic steroids. * Treatment with K+ supplements is not prohibited but the use should be continuously assessed throughout the trial. * Inability or unwillingness to undergo PET-CT imaging * Significant comorbidities that would interfere with participation * Pregnancy or breastfeeding * Unable to give informed consent